Insider Selling: Intra-Cellular Therapies Inc (ITCI) VP Sells 49,700 Shares of Stock

Intra-Cellular Therapies Inc (NASDAQ:ITCI) VP Lawrence J. Hineline sold 49,700 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $20.02, for a total value of $994,994.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Intra-Cellular Therapies Inc (NASDAQ:ITCI) opened at $19.65 on Wednesday. Intra-Cellular Therapies Inc has a 12 month low of $7.85 and a 12 month high of $22.67. The stock has a market capitalization of $1,070.00, a P/E ratio of -8.97 and a beta of 0.87.

ITCI has been the topic of several recent analyst reports. Zacks Investment Research raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $17.00 price target on the stock in a research note on Wednesday, November 8th. ValuEngine lowered Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 5th. SunTrust Banks raised Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research note on Wednesday, November 8th. BidaskClub lowered Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research note on Tuesday, December 12th. Finally, Canaccord Genuity initiated coverage on Intra-Cellular Therapies in a research note on Friday, December 15th. They issued a “buy” rating and a $31.00 price target on the stock. Two analysts have rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company. Intra-Cellular Therapies currently has a consensus rating of “Buy” and a consensus target price of $26.70.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in shares of Intra-Cellular Therapies by 21.5% during the fourth quarter. BlackRock Inc. now owns 4,002,920 shares of the biopharmaceutical company’s stock valued at $57,962,000 after acquiring an additional 709,048 shares in the last quarter. Wasatch Advisors Inc. increased its holdings in shares of Intra-Cellular Therapies by 18.7% during the third quarter. Wasatch Advisors Inc. now owns 1,970,181 shares of the biopharmaceutical company’s stock valued at $31,089,000 after acquiring an additional 310,668 shares in the last quarter. Millennium Management LLC increased its holdings in shares of Intra-Cellular Therapies by 18.0% during the fourth quarter. Millennium Management LLC now owns 1,454,944 shares of the biopharmaceutical company’s stock valued at $21,068,000 after acquiring an additional 221,980 shares in the last quarter. State Street Corp increased its holdings in shares of Intra-Cellular Therapies by 10.4% during the second quarter. State Street Corp now owns 1,004,360 shares of the biopharmaceutical company’s stock valued at $12,474,000 after acquiring an additional 94,763 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Intra-Cellular Therapies by 45.1% during the third quarter. Dimensional Fund Advisors LP now owns 938,980 shares of the biopharmaceutical company’s stock valued at $14,817,000 after acquiring an additional 291,793 shares in the last quarter. Hedge funds and other institutional investors own 76.93% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/21/insider-selling-intra-cellular-therapies-inc-itci-vp-sells-49700-shares-of-stock.html.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Insider Buying and Selling by Quarter for Intra-Cellular Therapies (NASDAQ:ITCI)

Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply